Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer

被引：41
|
作者：
Traina, Tiffany A.
Norton, Larry
Drucker, Karen
Singh, Buvanesh
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Breast Canc Med Serv, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Surg, Head & Neck Serv, New York, NY 10021 USA
来源：
ONCOLOGIST | 2006年 / 11卷 / 10期
关键词：
D O I：
10.1634/theoncologist.11-10-1070
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1070 / 1071
页数：2
相关论文
共 50 条
  • [31] VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysis
    dos Santos, Lucas Vieira
    Cruz, Marcelo Rocha
    Lopes, Gilberto de Lima
    da Silveira Nogueira Lima, Joao Paulo
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 151 (03) : 481 - 489
  • [32] VEGFR-1 polymorphisms as potential predictors of clinical outcome in bevacizumab-treated patients with metastatic pancreatic cancer
    Lambrechts, D.
    Delmar, P.
    Buysschaert, I.
    Claes, B.
    Yesilyurt, B. T.
    Verslype, C.
    Foernzler, D.
    Carmeliet, P.
    Scherer, S.
    Van Cutsem, E.
    EJC SUPPLEMENTS, 2009, 7 (03): : 10 - 10
  • [33] Intestinal Perforation due to Neutropenic Enterocolitis in a Patient Treated with Bevacizumab for Ovarian Cancer
    Sasaki, Akinori
    Harano, Kenichi
    Kogawa, Takahiro
    Matsubara, Nobuaki
    Naito, Yoichi
    Hosono, Ako
    Mukai, Hirofumi
    Yoshino, Takayuki
    Mukohara, Toru
    CASE REPORTS IN ONCOLOGICAL MEDICINE, 2020, 2020
  • [34] Nasal septum perforation in the patients with advanced breast cancer due to the treatment of lapatinib+capecitabine
    Oruc, Zeynep
    Kucukoner, Mehmet
    Urakci, Zuhat
    Kaplan, M. Ali
    Solmaz, Ihsan
    Isikdogan, Abdurrahman
    TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, 2015, 30 (01): : 21 - 24
  • [35] Fatal hemoptysis in a patient with breast cancer treated with bevacizumab and paclitaxel
    Philippin-Lauridant, G.
    Thureau, S.
    Ouvrier, M. -J.
    Blot, E.
    ANNALS OF ONCOLOGY, 2008, 19 (11) : 1977 - U10
  • [36] Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer
    Fang, Kunpeng
    Wang, Jie
    Yuan, Jianyong
    Sui, Chengjun
    Zhi, Jiajun
    Xia, Yong
    Sun, Minmin
    CANCER REPORTS, 2024, 7 (02)
  • [37] Association of antibiotic exposure with the mortality in bevacizumab-treated metastatic colorectal cancer: A secondary analysis from Dryad database.
    Sun, Chenyu
    Guo, Xianwei
    Kozma, Kelly
    Bhan, Chandur
    Kim, Na Hyun
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] NOTCH AND DLL4 EXPRESSION IN BEVACIZUMAB-TREATED COLON CANCER PATIENTS
    Negri, F. V.
    Bozzetti, C.
    Crafa, P.
    Pedrazzi, G.
    Porzio, R.
    Gardini, G.
    Tamagnini, I.
    Cavanna, L.
    Paties, C.
    Ardizzoni, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 216 - 217
  • [39] Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival
    Tadeu Ferreira Paiva
    Victor Hugo Fonseca de Jesus
    Raul Amorim Marques
    Alexandre André Balieiro Anastácio da Costa
    Mariana Petaccia de Macedo
    Patricia Maria Peresi
    Aline Damascena
    Benedito Mauro Rossi
    Maria Dirlei Begnami
    Vladmir Cláudio Cordeiro de Lima
    BMC Cancer, 15
  • [40] Intestinal perforation: an unusual adverse event of bevacizumab and paclitaxel combined therapy for a metastatic breast cancer
    Mychaluk, Johanna
    Piprot, Christine
    Sevestre, Henri
    Merviel, Philippe
    Gondry, Jean
    Fauvet, Raffaele
    PRESSE MEDICALE, 2009, 38 (09): : 1370 - 1374
12345